nach oben

Journal of Neural Transmission

Erschienen in:

01.11.2009 | Movement Disorders - Review Article

Beyond tremor and rigidity: non-motor features of Parkinson’s disease

verfasst von: Matthias Löhle, Alexander Storch, Heinz Reichmann

Erschienen in: Journal of Neural Transmission | Ausgabe 11/2009

Einloggen, um Zugang zu erhalten

Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disease and primarily considered as a movement disorder defined by the presence of motor symptoms, such as bradykinesia, tremor and rigidity. However, it is nowadays widely accepted that PD is associated with a wide variety of non-motor features, which affect the vast majority of patients during the course of the disease and may even precede the onset of motor symptoms. The spectrum of these non-motor disturbances is very broad and comprises neuropsychiatric conditions, such as depression, dementia and hallucinations, as well as autonomic, sensory and sleep disorders. Physicians need to be aware of these non-motor features, since they have substantial impact on the health-related quality of life of PD patients, even ahead of motor symptoms. This article aims to provide an overview of frequently observed non-motor features in PD and discusses prospects and limitations of currently available options for symptomatic treatment of these disturbances.

Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E (1999a) Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 14(10):866–874PubMed

Aarsland D, Larsen JP, Cummins JL, Laake K (1999b) Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 56(5):595–601PubMed

Aarsland D, Larsen JP, Tandberg E, Laake K (2000) Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc 48(8):938–942PubMed

Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P (2001) Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology 56(6):730–736PubMed

Aarsland D, Laake K, Larsen JP, Janvin C (2002) Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 72(6):708–712PubMed

Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60(3):387–392PubMed

Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 20(10):1255–1263PubMed

Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J (2003) Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord 18(3):287–293PubMed

Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP (2008) Epidemiology of Parkinson’s disease. J Neurol 255(Suppl 5):18–32PubMed

Antonini A, Tesei S, Zecchinelli A, Barone P, De Gaspari D, Canesi M et al (2006) Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson’s disease and depression: effect on quality of life. Mov Disord 21(8):1119–1122PubMed

Araki I, Kitahara M, Oida T, Kuno S (2000) Voiding dysfunction and Parkinson’s disease: urodynamic abnormalities and urinary symptoms. J Urol 164(5):1640–1643PubMed

Ashour R, Jankovic J (2006) Joint and skeletal deformities in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord 21(11):1856–1863PubMed

Ashour R, Tintner R, Jankovic J (2005) Striatal deformities of the hand and foot in Parkinson’s disease. Lancet Neurol 4(7):423–431PubMed

Bakshi R (1996) Fluoxetine and restless legs syndrome. J Neurol Sci 142(1–2):151–152PubMed

Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK et al (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148(5):1549–1557 discussion 64PubMed

Boeve BF, Silber MH, Ferman TJ (2003) Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 4(4):281–284PubMed

Bonin B, Vandel P, Kantelip JP (2000) Mirtazapine and restless leg syndrome: a case report. Therapie 55(5):655–656PubMed

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211PubMed

Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F et al (2005) Effect of levodopa on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord 20(12):1557–1563PubMed

Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P et al (2002) Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry 52(5):438–445PubMed

Brodsky MA, Godbold J, Roth T, Olanow CW (2003) Sleepiness in Parkinson’s disease: a controlled study. Mov Disord 18(6):668–672PubMed

Buysse DJ, Reynolds CFIII, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28(2):193–213PubMed

Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R et al (2002) The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 73(6):629–635PubMed

Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22(13):1901–1911PubMed

Chen P, Kales HC, Weintraub D, Blow FC, Jiang L, Mellow AM (2007) Antidepressant treatment of veterans with Parkinson’s disease and depression: analysis of a national sample. J Geriatr Psychiatry Neurol 20(3):161–165PubMed

Chou KL, Evatt M, Hinson V, Kompoliti K (2007) Sialorrhea in Parkinson’s disease: a review. Mov Disord 22(16):2306–2313PubMed

Comella CL (2002) Daytime sleepiness, agonist therapy, and driving in Parkinson disease. JAMA 287(4):509–511PubMed

Comella CL, Nardine TM, Diederich NJ, Stebbins GT (1998) Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson’s disease. Neurology 51(2):526–529PubMed

Defazio G, Berardelli A, Fabbrini G, Martino D, Fincati E, Fiaschi A et al (2008) Pain as a nonmotor symptom of Parkinson disease: evidence from a case–control study. Arch Neurol 65(9):1191–1194PubMed

den Hartog Jager W, Bethlem J (1960) The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans. J Neurol Neurosurg Psychiatry 23:283–290

Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P et al (2008) Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 23(6):850–857PubMed

Dodel R, Csoti I, Ebersbach G, Fuchs G, Hahne M, Kuhn W et al (2008) Lewy body dementia and Parkinson’s disease with dementia. J Neurol 255(Suppl 5):39–47PubMed

Dogu O, Apaydin D, Sevim S, Talas DU, Aral M (2004) Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. Clin Neurol Neurosurg 106(2):93–96PubMed

Doty RL, Shaman P, Dann M (1984) Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 32(3):489–502PubMed

Doty RL, Deems DA, Stellar S (1988) Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38(8):1237–1244PubMed

Drake ME (1988) Restless legs with antiepileptic drug therapy. Clin Neurol Neurosurg 90(2):151–154PubMed

Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA et al (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22(16):2314–2324PubMed

Duggal HS, Mendhekar DN (2007) Clozapine-associated restless legs syndrome. J Clin Psychopharmacol 27(1):89–90PubMed

Edwards LL, Quigley EM, Pfeiffer RF (1992) Gastrointestinal dysfunction in Parkinson’s disease: frequency and pathophysiology. Neurology 42(4):726–732PubMed

Eichhorn TE, Oertel WH (2001) Macrogol 3350/electrolyte improves constipation in Parkinson’s disease and multiple system atrophy. Mov Disord 16(6):1176–1177PubMed

Ellis T, Cudkowicz ME, Sexton PM, Growdon JH (2000) Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 12(3):364–369PubMed

Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP et al (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351(24):2509–2518PubMed

Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707 (quiz 837)PubMed

Ghazi-Noori S, Chung TH, Deane K, Rickards HE, Clarke CE (2003) Therapies for depression in Parkinson’s disease. Cochrane Database Syst Rev (3):CD003465

Ghorayeb I, Loundou A, Auquier P, Dauvilliers Y, Bioulac B, Tison F (2007) A nationwide survey of excessive daytime sleepiness in Parkinson’s disease in France. Mov Disord 22(11):1567–1572PubMed

Global Parkinson’s Disease Survey Steering Committee (2002) Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 17(1):60–67

Graham JM, Grunewald RA, Sagar HJ (1997) Hallucinosis in idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 63(4):434–440PubMed

Gugger JJ, Wagner ML (2007) Rapid eye movement sleep behavior disorder. Ann Pharmacother 41(11):1833–1841PubMed

Haehner A, Boesveldt S, Berendse HW, Mackay-Sim A, Fleischmann J, Silburn PA, Johnston AN, Mellick GD, Herting B, Reichmann H, Hummel T (2009) Prevalence of smell loss in Parkinson’s disease—a multicenter study. Parkinsonism Relat Disord 15(7):490–494

Hargrave R, Beckley DJ (1998) Restless leg syndrome exacerbated by sertraline. Psychosomatics 39(2):177–178PubMed

Herting B, Schulze S, Reichmann H, Haehner A, Hummel T (2008) A longitudinal study of olfactory function in patients with idiopathic Parkinson’s disease. J Neurol 255(3):367–370PubMed

Hobson P, Meara J (2004) Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom. Mov Disord 19(9):1043–1049PubMed

Hogl B, Saletu M, Brandauer E, Glatzl S, Frauscher B, Seppi K et al (2002) Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 25(8):905–909PubMed

Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry 70(6):734–738PubMed

Horiguchi J, Yamashita H, Mizuno S, Kuramoto Y, Kagaya A, Yamawaki S et al (1999) Nocturnal eating/drinking syndrome and neuroleptic-induced restless legs syndrome. Int Clin Psychopharmacol 14(1):33–36PubMed

Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH et al (2000) A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 54(8):1596–1602PubMed

Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G (1997) ‘Sniffin’ sticks’: olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses 22(1):39–52PubMed

Jacobs DM, Marder K, Cote LJ, Sano M, Stern Y, Mayeux R (1995) Neuropsychological characteristics of preclinical dementia in Parkinson’s disease. Neurology 45(9):1691–1696PubMed

Janvin CC, Aarsland D, Larsen JP (2005) Cognitive predictors of dementia in Parkinson’s disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol 18(3):149–154PubMed

Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14(6):540–545PubMed

Kalf JG, Smit AM, Bloem BR, Zwarts MJ, Munneke M (2007) Impact of drooling in Parkinson’s disease. J Neurol 254(9):1227–1232PubMed

Karatas M (2007) Restless legs syndrome and periodic limb movements during sleep: diagnosis and treatment. Neurologist 13(5):294–301PubMed

Katzenschlager R, Zijlmans J, Evans A, Watt H, Lees AJ (2004) Olfactory function distinguishes vascular parkinsonism from Parkinson’s disease. J Neurol Neurosurg Psychiatry 75(12):1749–1752PubMed

Khan NL, Katzenschlager R, Watt H, Bhatia KP, Wood NW, Quinn N et al (2004) Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurology 62(7):1224–1226PubMed

Kobal G, Hummel T, Sekinger B, Barz S, Roscher S, Wolf S (1996) “Sniffin’ sticks”: screening of olfactory performance. Rhinology 34(4):222–226PubMed

Kraus T, Schuld A, Pollmacher T (1999) Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine. J Clin Psychopharmacol 19(5):478–479PubMed

Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG (2006) Botulinum toxin type A for drooling in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 21(5):704–707PubMed

Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR (2003) Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord 18(4):414–418PubMed

Levy G, Tang MX, Cote LJ, Louis ED, Alfaro B, Mejia H et al (2000) Motor impairment in PD: relationship to incident dementia and age. Neurology 55(4):539–544PubMed

Levy G, Schupf N, Tang MX, Cote LJ, Louis ED, Mejia H et al (2002a) Combined effect of age and severity on the risk of dementia in Parkinson’s disease. Ann Neurol 51(6):722–729PubMed

Levy G, Jacobs DM, Tang MX, Cote LJ, Louis ED, Alfaro B et al (2002b) Memory and executive function impairment predict dementia in Parkinson’s disease. Mov Disord 17(6):1221–1226PubMed

Lewis SJ, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA (2005) Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 76(3):343–348PubMed

Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G (2003) A randomized trial of botulinum toxin A for treatment of drooling. Neurology 61(9):1279–1281PubMed

Magerkurth C, Schnitzer R, Braune S (2005) Symptoms of autonomic failure in Parkinson’s disease: prevalence and impact on daily life. Clin Auton Res 15(2):76–82PubMed

Mahieux F, Fenelon G, Flahault A, Manifacier MJ, Michelet D, Boller F (1998) Neuropsychological prediction of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 64(2):178–183PubMed

Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G et al (2003) Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18(6):685–688PubMed

Marder K, Tang MX, Cote L, Stern Y, Mayeux R (1995) The frequency and associated risk factors for dementia in patients with Parkinson’s disease. Arch Neurol 52(7):695–701PubMed

Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM (2003) Assessment of sleep and sleepiness in Parkinson disease. Sleep 26(8):1049–1054PubMed

Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A (2009) A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 72(10):886–892PubMed

Merims D, Shabtai H, Korczyn AD, Peretz C, Weizman N, Giladi N (2004) Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease. J Neural Transm 111(10–11):1447–1453PubMed

Merims D, Balas M, Peretz C, Shabtai H, Giladi N (2006) Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol 29(6):331–337PubMed

Merino-Andreu M, Arnulf I, Konofal E, Derenne JP, Agid Y (2003) Unawareness of naps in Parkinson’s disease and in disorders with excessive daytime sleepiness. Neurology 60(9):1553–1554PubMed

Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K et al (2006) Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66(7):996–1002PubMed

Morgante L, Epifanio A, Spina E, Di Rosa AE, Zappia M, Basile G et al (2002) Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson’s disease. Neurol Sci 23(Suppl 2):S89–S90PubMed

Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R et al (2004) Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 27(4):153–156PubMed

Negre-Pages L, Regragui W, Bouhassira D, Grandjean H, Rascol O (2008) Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord 23(10):1361–1369PubMed

Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J (2002) Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 17(5):1031–1035PubMed

Ondo WG, Hunter C, Moore W (2004) A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology 62(1):37–40PubMed

Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G (2005) Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord 20(8):958–963PubMed

Paik IH, Lee C, Choi BM, Chae YL, Kim CE (1989) Mianserin-induced restless legs syndrome. Br J Psychiatry 155:415–417PubMed

Papapetropoulos S, Mash DC (2005) Psychotic symptoms in Parkinson’s disease. From description to etiology. J Neurol 252(7):753–764PubMed

Papapetropoulos S, Katzen H, Schrag A, Singer C, Scanlon BK, Nation D et al (2008) A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson’s disease. BMC Neurol 8:21PubMed

Parkinson J (1817) An essay on the shaking palsy. Sherwood, Neely, and Jones, London

Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U (2003) Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s disease. Mov Disord 18(6):659–667PubMed

Perroud N, Lazignac C, Baleydier B, Cicotti A, Maris S, Damsa C (2007) Restless legs syndrome induced by citalopram: a psychiatric emergency? Gen Hosp Psychiatry 29(1):72–74PubMed

Pinninti NR, Mago R, Townsend J, Doghramji K (2005) Periodic restless legs syndrome associated with quetiapine use: a case report. J Clin Psychopharmacol 25(6):617–618PubMed

Pollak P, Tison F, Rascol O, Destee A, Pere JJ, Senard JM et al (2004) Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75(5):689–695PubMed

Prohorov T, Klein C, Miniovitz A, Dobronevsky E, Rabey JM (2006) The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol 253(2):171–175PubMed

Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C (2007) Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord 22(3):313–318PubMed

Razmy A, Lang AE, Shapiro CM (2004) Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 61(1):97–102PubMed

Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23(2):183–189 quiz 313PubMed

Reijnders JS, Ehrt U, Lousberg R, Aarsland D, Leentjens AF (2009) The association between motor subtypes and psychopathology in Parkinson’s disease. Parkinsonism Relat Disord 15(5):379–382PubMed

Rich SS, Friedman JH, Ott BR (1995) Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. J Clin Psychiatry 56(12):556–559PubMed

Richard IH, Kurlan R (1997) A survey of antidepressant drug use in Parkinson’s disease. Parkinson Study Group. Neurology 49(4):1168–1170PubMed

Riedel O, Klotsche J, Spottke A, Deuschl G, Forstl H, Henn F et al (2008) Cognitive impairment in 873 patients with idiopathic Parkinson’s disease. Results from the German Study on Epidemiology of Parkinson’s Disease with Dementia (GEPAD). J Neurol 255(2):255–264PubMed

Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K et al (2008) Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 63(2):167–173PubMed

Santamaria J, Tolosa E, Valles A (1986) Parkinson’s disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 36(8):1130–1133PubMed

Sanz-Fuentenebro FJ, Huidobro A, Tejadas-Rivas A (1996) Restless legs syndrome and paroxetine. Acta Psychiatr Scand 94(6):482–484PubMed

Schenck CH, Bundlie SR, Mahowald MW (1996) Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46(2):388–393PubMed

Schestatsky P, Kumru H, Valls-Sole J, Valldeoriola F, Marti MJ, Tolosa E et al (2007) Neurophysiologic study of central pain in patients with Parkinson disease. Neurology 69(23):2162–2169PubMed

Shpirer I, Miniovitz A, Klein C, Goldstein R, Prokhorov T, Theitler J et al (2006) Excessive daytime sleepiness in patients with Parkinson’s disease: a polysomnography study. Mov Disord 21(9):1432–1438PubMed

Shulman LM, Taback RL, Bean J, Weiner WJ (2001) Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov Disord 16(3):507–510PubMed

Stern Y, Marder K, Tang MX, Mayeux R (1993) Antecedent clinical features associated with dementia in Parkinson’s disease. Neurology 43(9):1690–1692PubMed

Stevens S, Cormella CL, Stepanski EJ (2004) Daytime sleepiness and alertness in patients with Parkinson disease. Sleep 27(5):967–972PubMed

Suchowersky O, Furtado S, Rohs G (1995) Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson’s disease. Mov Disord 10(3):337–340PubMed

Tan EK, Lum SY, Fook-Chong SM, Teoh ML, Yih Y, Tan L et al (2002) Evaluation of somnolence in Parkinson’s disease: comparison with age- and sex-matched controls. Neurology 58(3):465–468PubMed

Tandberg E, Larsen JP, Karlsen K (1998) A community-based study of sleep disorders in patients with Parkinson’s disease. Mov Disord 13(6):895–899PubMed

Tandberg E, Larsen JP, Karlsen K (1999) Excessive daytime sleepiness and sleep benefit in Parkinson’s disease: a community-based study. Mov Disord 14(6):922–927PubMed

The Parkinson Study Group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 340(10):757–763

Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS et al (2008) Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 23(16):2267–2302PubMed

Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA (1995) Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 14(2):131–139PubMed

Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ (2007) Patient-reported autonomic symptoms in Parkinson disease. Neurology 69(4):333–341PubMed

Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ (2004) Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov Disord 19(11):1306–1312PubMed

Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F (1988) Parkinson’s disease: the presence of Lewy bodies in Auerbach’s and Meissner’s plexuses. Acta Neuropathol 76(3):217–221PubMed

Weintraub D, Stern MB (2005) Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry 13(10):844–851PubMed

Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB (2004) Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J Am Geriatr Soc 52(5):784–788PubMed

Wetter TC, Brunner J, Bronisch T (2002) Restless legs syndrome probably induced by risperidone treatment. Pharmacopsychiatry 35(3):109–111PubMed

Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J et al (2007) IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 69(4 Suppl 1):S14–S22PubMed

Zangaglia R, Martignoni E, Glorioso M, Ossola M, Riboldazzi G, Calandrella D et al (2007) Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov Disord 22(9):1239–1244PubMed

Titel: Beyond tremor and rigidity: non-motor features of Parkinson’s disease
verfasst von: Matthias Löhle
Alexander Storch
Heinz Reichmann
Publikationsdatum: 01.11.2009
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 11/2009
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-009-0274-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2009

The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia

Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson’s disease drug, rasagiline compared with selegiline, in the rat midbrain

Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate

Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival

Is phosphoadenosine phosphate phosphatase a target of lithium’s therapeutic effect?